Global Insomnia Therapeutics Market 2024-2028
The insomnia therapeutics market is forecasted to grow by USD 1103.4 mn during 2023-2028, accelerating at a CAGR of 5.72% during the forecast period. The report on the insomnia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of insomnia, technological advancements in diagnostics and treatment, and rising healthcare expenditure and insurance coverage.
Technavio's insomnia therapeutics market is segmented as below:
- By Type
- Drug
- Devices
- By Distribution Channel
- Prescription
- OTC
- By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
This study identifies the increased focus on non-pharmacological treatments as one of the prime reasons driving the insomnia therapeutics market growth during the next few years. Also, technological advancements in sleep monitoring and tracking and growing awareness and acceptance of importance of mental health will lead to sizable demand in the market.
The report on the insomnia therapeutics market covers the following areas:
- Insomnia therapeutics market sizing
- Insomnia therapeutics market forecast
- Insomnia therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading insomnia therapeutics market vendors that include Abbott Laboratories, Astellas Pharma Inc., Aurobindo Pharma Ltd., Eisai Co. Ltd., Electromedical Products International Inc., Idorsia Pharmaceuticals Ltd., INNOVATIVE NEUROLOGICAL DEVICES LLC, Mallinckrodt Plc, MEDICE Arzneimittel Putter GmbH and Co. KG, Merck and Co. Inc., Minerva Neurosciences Inc., Neurim Pharmaceuticals Ltd., Pfizer Inc., Questex LLC, Sanofi SA, Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., and Viatris Inc.. Also, the insomnia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.